Verastem, Inc. , focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that it will present new data at the 12th International Mesothelioma Interest Group Conference being held October 22-24, 2014, in Cape Town, South Africa. "Determination of Biomarker response in a Phase II Window of Opportunity Study of Defactinib , a Focal Adhesion Kinase Inhibitor, in Subjects with Resectable MPM" Investigators and members of the Verastem leadership team will give oral presentations discussing the Company's development programs targeting cancer stem cells with a focus on lead inhibitor VS-6063 .
http://ift.tt/1xoBkk3
http://ift.tt/1xoBkk3
No comments:
Post a Comment